Scynexis secured a new BARDA contract worth $214 million to develop a treatment for invasive fungal infections. The award expands federal support for SCY-247, which Scynexis is developing with BARDA backing to address serious, drug-resistant fungal disease where treatment options can be limited. The contract underscores continued U.S. government focus on antimicrobials and antifungals through accelerated development funding and lifecycle partnerships. For Scynexis, the agreement strengthens its runway for clinical and manufacturing work required for late-stage progression.